World Economic Forum Grants AgroAmerica the New Champions Award
10.11.2021 22:07:00 EET | Business Wire | Press release
AgroAmerica received the New Champions Award 2021 – in the category of Excellence in Social Responsibility for the Human Development Center -HDC- project, which consists of a medical clinic, research facility, and a school for worker's children, promoting health, education, and development in the Southwestern region of Guatemala.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110006209/en/
AgroAmerica’s Human Development Center project received the New Champions Award 2021 endorsed by the World Economic Forum in the category of Excellence in Social Responsibility. A project built in 10ha of land donated by AgroAmerica for the construction of a Medical Clinic, Research Center and school for worker’s children in Southwestern Guatemala. (Photo: Business Wire)
Since its opening in 2014, the Center has been managed in alliance comprising the University of Colorado, Project Cure, Foundation for the Comprehensive Health of Guatemalans – Funsalud- and Agroamerica, aiming to contribute to the Sustainable Development Goals .
To date, the clinic has provided a range of services for more than 35,000 patients, including medical treatments, dental care, and a childbirth center. The community programs focus on mother and child health and youth development; from 2014 to 2020, 3,343 children and 1,976 women have participated in the programs to decrease maternal and infant mortality and improve the nutritional status of the area; the local level of child malnourishment has been dramatically reduced from the national average of 50% .
The Research Center complements the actions of the HDC. The main objective is to scientifically investigate the root causes of the health problems observed in the region by measuring the incidence of diseases such as Zika, Chikungunya, Dengue, diarrhea, and most recently, COVID-19, to develop action plans to eradicate them.
"We are beyond honored," said Fernando Bolaños, AgroAmerica CEO. "Recognitions like these move and inspire other organizations, companies, and individuals to join and act to positively impact our environment and set worldwide standards for sustainable business, corporate governance, innovation, and social responsibility. Congratulations to all the New Champions!"
WEF New Champions
World Economic Forum New Champion companies are dynamic high-growth companies that are championing new business models, emerging technologies, and sustainable growth strategies in the Fourth Industrial Revolution.
The New Champions award is an initiative to identify and reward exceptional efforts by members of the New Champions Community in sending strong market signals and scaling innovative solutions for revitalizing our societies, accelerating technology and innovation, and promoting responsible corporate governance. See World Economic Forum’s New Champions award announcement here.
About AgroAmerica:
AgroAmerica is a family-owned, diversified, and vertically integrated Corporation in the agro-industrial production, processing, commercialization, and distribution of sustainable food and ingredients of the highest quality committed to contributing to the well-being of people and nature through Corporate Social Responsibility. https://agroamerica.com/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110006209/en/
Contact information
Javier Aguirre
sustainability@agroamerica.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 20:09:00 EET | Press release
Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results while favouring its own Google Shopping product, causing sustained and quantifiable commercial damage to PriceRunner over mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom